Journal of Clinical Pediatrics >
Analysis of risk factors for early death of acute promyelocytic leukemia in children
Received date: 2022-05-09
Online published: 2024-01-05
Objective To analyze the clinical characteristics of early death in newly diagnosed children with acute promyelocytic leukemia (APL), and to explore the direct causes of death and the risk factors leading to early death. Methods The clinical data of newly diagnosed APL children admitted from January 2013 to December 2020 were retrospectively analyzed. Results A total of 103 children with APL (56 boys and 47 girls) were included. The median age of onset was 9.0 (7.0-13.0) years old. There were 24, 41 and 38 children in low, medium and high risk groups, respectively. Early death occurred in 13 children. Compared with the survival group, the early death group had higher proportions of initial white blood cell count (WBC) ≥100×109/L, prothrombin time (PT) ≥3 s, D-dimer ≥9mg/L, bone marrow promyelocytes percentage ≥90%, and high risk, and the differences were statistically significant (P<0.05). Among the 13 children who died early, 10 were boys and 3 were girls. The median time from diagnosis to death was 4.0 (2.0-7.0) days. All the 13 children died of hemorrhage, including 13 cases of intracranial hemorrhage and 5 cases of intracranial hemorrhage combined with pulmonary hemorrhage. Multivariate logistic regression analysis showed that WBC≥10×109/L at first diagnosis (OR=17.27, SE=1.12, 95%CI: 1.92-155.04) was an independent risk factor for early death. Conclusions The early case fatality rate of children with APL is high, and WBC≥10×109/L at first diagnosis is an important predictor of early death in children with APL.
Key words: acute promyelocytic leukemia; early death; child
Qianghua YAO , Yingchao WANG , Dao WANG , Yufeng LIU . Analysis of risk factors for early death of acute promyelocytic leukemia in children[J]. Journal of Clinical Pediatrics, 2024 , 42(1) : 53 -57 . DOI: 10.12372/jcp.2024.22e0649
[1] | Thomas X. Acute promyelocytic leukemia: a history over 60 years-from the most malignant to the most curable form of acute leukemia[J]. Oncol Ther, 2019, 7(1): 33-65. |
[2] | Testi AM, D'Angiò M, Locatelli F, et al. Acute promyelocytic leukemia (APL): comparison between children and adults[J]. Mediterr J Hematol Infect Dis, 2014, 6(1): e2014032. |
[3] | Jillella AP, Kota VK. The global problem of early deaths in acute promyelocytic leukemia: a strategy to decrease induction mortality in the most curable leukemia[J]. Blood Rev, 2018, 32(2): 89-95. |
[4] | 中华医学会血液学分会, 中国医师协会血液科医师分会. 中国急性早幼粒细胞白血病诊疗指南(2018年版)[J]. 中华血液学杂志, 2018, 39(3): 179-183. |
[5] | Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracyclinedrags for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups[J]. Blood, 2000, 96(4): 1247-1253. |
[6] | Gill H, Yung Y, Chu HT, et al. Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study[J]. Blood Adv, 2021, 5(14): 2829-2838. |
[7] | Abla O, Ribeiro RC, Testi AM, et al. Predictors of thrombo hemorrhagic early death in children and adolescents with t (15; 17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy[J]. Ann Hematol, 2017, 96 (9): 1449-1456. |
[8] | Dhakal P, Lyden E, Rajasurya V, et al. Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?[J]. Leuk Lymphoma, 2021, 62 (8): 1949-1957. |
[9] | Nasir SS, Giri S, Nunnery S, et al. Outcome of adolescents and young adults compared with pediatric patients withacute myeloid and promyelocytic leukemia[J]. Clin Lymphoma Myeloma Leuk, 2017, 17(2): 126-132. |
[10] | de Azevedo AC, Matsuda E, Cervellini JY, et al. Early mortality in children and adolescents with acute promyelocytic leukemia: experience of the Boldrini children's center[J]. J Pediatr Hematol Oncol, 2020, 42(7): e641-e646. |
[11] | Sanz MA, Montesinos P. Advances in the management of coagulopathy in acute promyelocytic leukemia[J]. Thromb Res, 2020, 191(Suppl 1): S63-S67. |
[12] | Mantha S, Goldman DA, Devlin SM, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukaemia in the ATRA era[J]. Blood, 2017, 129(13): 1763-1767. |
[13] | Baysal M, Gürsoy V, Hunutlu FC, et al. The evaluation of risk factors leading to early deaths in patients with acute promyelocytic leukemia: a retrospective study[J]. Ann Hematol, 2022, 101(5): 1049-1057. |
[14] | Creutzig U, Zimmermann M, Dworzak M, et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses[J]. Br J Haematol, 2010, 149(3): 399-409. |
[15] | Zhang ZX, Lu AD, Wu J, et al. Retrospective analysis of data from 73 patients with childhood acute promyelocytic leukaemia receiving modified chemotherapy: a single-centre study[J]. J Cancer Res Clin Oncol, 2021, 147(4): 1189-1201. |
[16] | 王静, 贾月萍, 刘桂兰, 等. 不同方案诱导治疗儿童急性早幼粒细胞白血病的临床分析[J]. 临床儿科杂志, 2014, 32(5): 405-409. |
[17] | 张丽, 竺晓凡. 我如何治疗儿童急性早幼粒细胞白血病[J]. 中华血液学杂志, 2020, 41(10): 793-797. |
[18] | Hou J, Wang S, Zhang Y, et al. Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide[J]. Ann Hematol, 2017, 96(12): 2005-2013. |
[19] | Ciftciler R, Haznedaroglu IC, Aksu S, et al. The factors affecting early death in newly diagnosed APL patients[J]. Open Med (Wars), 2019, 14: 647-652. |
[20] | Hou W, Zhang Y, Jin B, et al. Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone[J]. Blood Cells Mol Dis, 2019, 79: 102351. |
/
〈 |
|
〉 |